Try our Advanced Search for more refined results
Life Sciences - March, 2018
366 articles
- Kimberly-Clark Won't Face Suit Over Ebola Prevention Gowns
- Co. Punished For Dodging Discovery Tied To $75M IP Loss
- Pharmacy Owner Gets 13 Years For $4.3M Kickback Plot
- Reckitt Doesn't Own Airborne's Box Design: Supplement Co.
- Ex-Katten Atty Should Hand Over A Half-Million, Feds Say
- Gov't Can't Expand FCA Case Over Hep B Tests, Judge Says
- Goodwin Liu Talks Academia, Constitutional Law, Oxtail Stew
- Costco Asks 9th Circ. To Bury Supplement False Ad Suit
- Bard Owes Injured Woman $3.6M In IVC Bellwether, Jury Finds
- Ex-Fed. Circ. Chief On Court's Fading Power, 101 Woes
- Why Bristol-Myers Applies To Federal Class Actions
- BigLaw Doesn't Have A Diversity Problem
- First Bard Vein Filter Bellwether Heads To Jury
- Parents Can Sue Sorin Over Heart-Valve Death, Judge Says
- WashU, WARF Offer Closing Arguments In Patent Royalty Trial
- Mylan Must Face Many Of Investors' EpiPen Fraud Claims
- Trial Court Disrespected China, Exporters Tell Justices
- Cozen O'Connor Adds LeClairRyan IP Attorney In D.C.
- 9th Circ. Revives $3M In Damages Against IKOR, Execs
- Shook Hardy Adds Life Sciences, Food & Bev Pro In Philly
- Roman J. Israel, Esquire, Meet Donald J. Trump, POTUS
- Impax Ends Acne Drug Pay-For-Delay Suit For $20M
- Theranos Indirect Investors Seek Cert. In Securities Suit
- Bard Exec Defends Handling Of Complaints At Vein Filter Trial
- Whistleblower Atty Says Shield 'Came Up With' FCA Scheme
- Pharmacies Again Sue Express Scripts After Talks Fail
- Bayer Unit Wins $17.6M Over Herbicide Supplier Price Hikes
- Biotech Co. In Contempt For Public Statements On IP Row
- Deals Rumor Mill: GSK, Platinum Equity, Gazprom
- Teva Skirts $235M Infringement Verdict In Coreg Patent Row
- Johnson & Johnson Can't Escape Benecol Labeling Suit
- Judge OKs Drug Distributor Info Sharing In Opioid MDL
- Fed. Circ. Pauses PTAB Review Of Restasis Patents
- Chinese Streaming Co. Leads 4 IPOs Netting $828M
- Essure Users Must Combine 13K Injury Suits, Judge Says
- Biz Misled On Gene Therapy Toxicity Pre-IPO, Investors Say
- Biogen Lacked Intent To Defraud, Shareholder Suit Judge Says
- Pharmacy Owner Gets 5 Years For $10.5M Tricare Fraud
- Timing Of Patent-Eligibility Challenges In Pharma Cases
- We Need A Cybersecurity Framework For Law Firms
- How NY And NJ Medical Cannabis Regulations Are Evolving
- US Chips Away At S. Korean Car, Drug Barriers
- Cherokee Say Opioid Claims Don't Belong In Federal Court
- ​​​​​​​Anxiety Patients, Others Now Qualify For NJ Medical Pot
- Equity Partnership Isn't What It Used To Be
- GSK Buys Out Novartis Stake In Healthcare JV For $13B
- Ex-Workers Press For Sanctions In Colgate ERISA Suit
- Examining Exergen For Patent Eligibility Clues
- GSK Has One Week To Hand Over Zofran Data, Judge Says
- Clinics May Eye Quick Deals In Lost Embryo Cases
- Shkreli To Appeal Fraud Conviction, 7-Year Prison Sentence
- Investors Battle Intuitive On Bid For Win In Stock-Drop Suit
- SEC Settles With Drugmaker Akorn Over Revenue Reports
- Medical Device Co. Must Face Claims In Hip Implant MDL
- WashU Kicks Off Trial Over Drug Patent Licensing Royalties
- CytRx Scoffs At $685K Fees Request In Shareholder Suit
- Diagnostic Lab Escapes Suit Over Cancer Misdiagnosis
- Generic Cos. Tell Fed. Circ. Not To Halt PTAB Restasis IPRs
- 6 Companies Fill IPO Pipeline With Filings Totaling $656M
- Colgate Says No Sanctions Warranted In ERISA Suit
- Doc Charged In Insys Case Gets Limited Prescription Power
- PacBio DNA Patent Survives Eligibility Challenge, Judge Finds
- Regeneron Must Pay Attys' Fees After 'Severe Misconduct'
- Boehringer Wins 1st Bellwether In Conn. Pradaxa Risk Suit
- Biogen Wants Jury Verdict Overruled In MS Drug Patent Row
- Is The US Patent System In Trouble? Part 2
- Consumers Push For Cert. In Contaminated Ranbaxy Pills Suit
- Pharma Co. Escapes NY Derivative Suit Over Director Pay
- AbbVie Ordered To Pay $3M In AndroGel Retrial
- Higher Ed Should Approach Marijuana Laws Cautiously
- NuVasive Investors Settle Kickback Class Action For $7.9M
- Judging A Book: Hardiman Reviews 'Without Precedent'
- CVS, Walgreens, Rite Aid Settle Impax Pay-For-Delay Suit
- Vitamin C Case Brings A First For China, US Supreme Court
- Ensnarement Defense Violates Jury Trial Right, Justices Told
- Drugmaker's Investors Sue For Books On $885M In Sanctions
- New FDA Policy Takes Aim At Big Compounders
- Is The US Patent System In Trouble? Part 1
- Pa. Court Won't Rethink Axing Bar On Risperdal Punitives
- Bayh-Dole Could Be A Drug Pricing Fix, If The Feds Want It
- Trump Says Fed. Gov't Will Sue Drugmakers Over Opioids
- Doc Lands 8 Years, Owes $9M For Shady Medicare Billing
- 6 Firms To Lead 8 IPOs Exceeding $3.5B As Deals Heat Up
- Alvogen Beats Infringement Suit Over Suboxone Generic
- 2nd Circ. Affirms Dismissal Of Organic Baby Food Claims
- Alere, Feds Reach $33.2M Deal In Medical Device FCA Suit
- Cherokee Push Judge To Send Opioid Suit To State Court
- Top Tax Changes For Law Firms: What Lawyers Need To Know
- Roundup Warning Label Ruling Less Surprising Than It Seems
- Alice Angst Intensifies
- Creditor Loses Bid For Nearly $4M Of BioChemics-SEC Deal
- 4 Highlights From Congress' Two-Day Opioid Hearing
- AbbVie Must Be Sent Message, Jury Told In AndroGel Trial
- Shire Wins Adderall Suit While Loser Gets Sanction Request
- Law360's Life Sciences Editorial Advisory Board
- 5th Circ. Rejects IRS Bid To Pause Anti-Inversion Appeal
- FTC's Big ViroPharma Loss Has Antitrust Silver Lining
- Gibson Dunn DQ Sought By Ex-Pharma Execs In RICO Suit
- 6 Consumer Protection Enforcement Trends To Watch At FTC
- Shkreli Cuts $1.5M Deal To End KaloBios Investors' Suit
- Discovery Challenges In Transnational Class Actions
- Companies Should Avoid The BigLaw Bonus Structure
- House Passes 'Right To Try' Experimental Treatments Bill
- Fed. Circ. Says Drug Co. Briefs Too Long In Suboxone Appeal
- Israeli Pharma Co., CEO Can't Escape Stock-Drop Suit
- PTAB Deems 2 Rulings Nixing AIA Reviews 'Informative'
- Vitamin World Creditor Seeks To Convert Ch. 11 To Ch. 7
- Ark. Sues Drugmakers, Distributors Over Opioid Epidemic
- Gov't Slams Ex-Katten Atty's Move To Nix Conviction
- Ill. Man Says Insys Rep's Lies Got Him Hooked On Opioids
- Puma Biotech Insider Trader Pays Penalty, Can Go Home
- Fed. Circ. Says No Fees For PTAB Indefiniteness Finding
- Meningitis Pharmacist's Direct Victims Were Providers: Judge
- Atty's Widow Says Mass. Court Buoys Her $3M GSK Verdict
- A Potentially Promising Future For Pa. Medical Marijuana
- Calif. Medical Supplier Fights DOJ's Entry Into FCA Suit
- IRS Asks 1st Circ. To Uphold Order To Return Excess Subsidy
- Sessions Memo Backs Death Penalty In Opioid Cases
- Endo, Others Ink $166M Lidoderm Pay-For-Delay Settlements
- Globus Recruits Violating Noncompete Deals, DePuy Says
- Chief Innovation Officer — The New Star On Legal Teams
- Reps. Introduce Wide-Ranging Bill To Bolster Patent Owners
- More Sharing Of Opioid Sales Data Possible, DEA Chief Says
- FTC Loses Assault On Shire Unit's Serial FDA Petitions
- Firms Clamor To Lead Cancer Drug Stock-Drop Suit In Boston
- Medicaid Rule Can't Govern Radioactive Drugs, Suit Says
- Blue Cross Unit Fights Sanctions Bid In Aggrenox MDL
- Allergan Drug Buyers Urge 1st Circ. To Keep Class Cert.
- Relator Assails Early Out For Janssen, J&J In Off-Label Row
- FDA Warning Wire: Birds And Bugs Plague Drug Plant
- Walgreens Strikes $5.5M Drug Overcharge Deal With Mass. AG
- Momenta, Sandoz Can't Dodge Amphastar Antitrust Suit
- EXCLUSIVE: Behind The Downfall Of Latham's Chairman
- It's Time For The US To Re-Engage With The TPP
- Acetris Questions Made-In-US Standard For Drugs
- Eligibility Rulings May Lead To Shift In Patent Prosecution
- National Lawyers Need National Licensing For National Courts
- How Regulatory Power Is Moving To The States
- Mass. Court Ruling Eases Way For Brand Drug Label Claims
- Valeant, Pershing Get Initial OK On $290M Investor Deals
- AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says
- Co. Did Not Warn Of Mesh Product Risks, NJ Jury Told
- 'China's Netflix' Leads 6 IPO Launches Exceeding $3B Total
- Experts Didn't Prove Hernia Mesh Caused Injuries, Court Says
- Rite Aid Defends Rx Discount Program In Co-Pay Cost Row
- Oglala Sioux Tribe Targets Drug Cos. With Opioid Suit
- Treasury Urges 5th Circ. To Reinstate Anti-Inversion Rule
- Clyde & Co. Nabs Ex-Curtis Int'l Arbitration Pro In Paris
- Trump Unveils 4-Point Plan For Easing Opioid Crisis
- Illumina Says Sales Ban Needed To Stop Ariosa Infringement
- Tribe Asks Fed. Circ. To Pause Restasis Patent Reviews
- High Court Won't Hear Two Consumer Protection Suits
- Doc Can Opine In Diet Pill Death Suit, NJ Appeals Court Says
- Acne Med Pay-For-Delay Deal Sped Up Generic, Exec Says
- High Court Won't Review FCA First-To-File Case
- Teva Can't Get Justices To Nix Suit Alleging Drug-Cancer Link
- Western Pa. Cities Latest To Strike At Opioid Manufacturers
- Justices Refuse To Hear Pot Co.'s Challenge Of IRS Probe
- Opioid Solutions: Insurance, Legislation Or Litigation?
- NJ Employers Should Note Evolving Cannabis Laws
- When 'A' Stands For Preemption
- Private Equity FCA Suit More Likely Outlier Than Omen
- SEC's Silicon Valley Scrutiny Comes To Bloom In New Cases
- Philly Litigator Rips Opioid Defense Attys At Conference
- 'Unicorn' Zscaler Surges After Pricing Upsized $192M IPO
- Pharma Cos. Liable For Generic Labels, Mass. Top Court Says
- Optical Co. Says Ex-Biz Partner's IP Suit Too Late
- Summary Judgment Denial Clears Path For Abilify Trials
- Hospital Seeks Data On Worker Fired After Skipping Flu Shot
- Drug Cos. Say Cherokee Opioid Suit Must Stay In Fed. Court
- Hernia Mesh Maker Can't Force Chubb Unit To Cover IP Suit
- NY Docs Got Lap Dances, Booze From Insys, DOJ Says
- Aegerion Placed Under Supervision In Misbranding Settlement
- Feds Should Own Gilead Hep C Patent, Nonprofit Says
- Robins Kaplan Adds Ex-Kasowitz Benson IP Pro In Calif.
- Fed. Circ. Affirms Exergen Ruling Doesn't Set Precedent
- 4 Firms To Steer IPOs Totaling $850M Led By Dropbox
- Stock-Drop Suit Targeting HeartWare Survives Dismissal Bid
- A Chat With Littler Info Chief Durgesh Sharma
- PE Firm Platinum Offers $2.1B For J&J Glucose Testing Unit
- Changes To Rule 23 Are Coming, Are You Prepared?
- 9th Circ. Urged To Rethink HIPAA Probe Coverage Ruling
- 9th Circ. Revives Whistleblower's FCA Row Against Merck
- Bankrupt Laser Co. Hid Assets To Duck Court Judgments: Suit
- Dem Bill Takes On Tribal Opioid Crisis With New Program
- Menominee Latest Tribe To Sue Pharma Cos. Over Opioids
- Cigna, Express Scripts To Face Tough Antitrust Review
- GSK Says FDA Barred Warning Of Suicide Risks With Paxil
- Deals Rumor Mill: Alibaba, Bayer, BP
- Consultant Co. Wants Out Of $1.76M Suit Over Alleged Scam
- Drugmakers Get Blowback As 340B Changes Gain Steam
- Abbott Says Ex-Employee Should Pay For Dismissed FCA Suit
- Investors Can't Peg ProNAi For Failed Cancer Drug
- Calif. Duty To Defend Is In Jeopardy
- Personal Jurisdiction In 3rd Circ. After 'Shuker'
- Collaborative Workspace Co. Scores $58M In Global Push
- VC Firm Flagship Commits $50M To Gene Control Researcher
- False Claims Act An Unlikely Tool In Opioid Crackdown
- Fed. Circ. Backs PTAB In Upholding Uterine Endoscope IP
- Tax Court Flubbed Analysis In Medtronic Case, 8th Circ. Told
- Tribes Need Gov't Funding To Fight Opioids, Senate Panel Told
- New AHIP Chief Dishes On Health Policy Vision
- GSK Says It Can't Find Marketing Contracts In Zofran MDL
- Deals Rumor Mill: Siemens, Deutsche Bank, Ardian
- Second Fertility Clinic Sued Over Destroyed Eggs
- Theranos CEO Holmes Settles Over $700M Fraud, SEC Says
- Idexx Underpaid Lyme Disease Patent Royalties, UT Says
- What To Expect From DOJ Shift In Marijuana Enforcement
- Trends In China's Food And Packaging Laws: Part 1
- Orexigen Gets Interim OK For $7.5M DIP To Fund Sale Process
- Shkreli's Sentence Shows Risks Of Open Defiance
- Ex-NFLer, Atty Fight SEC's Stock Scam Wins At 9th Circ.
- Illumina Tells Fed. Circ. Ariosa Doesn't Deserve 2nd Chance
- Judge Schedules First 3 Trials In Abilify MDL
- House Fails To Pass 'Right-To-Try' Bill After Dems Object
- 7th Circ. Affirms Fired Atty's Fee After Second Review
- Tikehau Nabs $50M For Health-Focused VC Fund
- Opioid Bills Would Up Feds' Control Over Quotas, Imports
- Generic Drug Co. Can Continue Arbitration Against Ranbaxy
- FDA Warning Wire: Online Eye Exam Gets Agency Side-Eye
- Oregon Enacts Drug Price Transparency Law
- Tribe Says Opioid Makers Caused 'Public Health Crisis'
- Lawyering A La Carte: Unbundled Dispute Resolution Services
- Cigna Must Face RICO Claims In Insured Price Suit
- FCA Materiality May Return To High Court
- Syngenta Agrees To Pay $1.5B To End Corn GMO Class Claims
- Ohio Pension OK'd To Lead Investors Against Mallinckrodt
- Recent Patent-Eligibility Cases Leave Unanswered Questions
- $40M Acne Med Pay-For-Delay Trial Kicks Off In Boston
- PTAB Denies Coherus' Challenge To 2 Enbrel Patents
- Pharmacist, Employee Get Prison For $30M Tricare Fraud
- EU Says Pay-For-Delay Drug Settlements Still Down
- Drugmaker Orexigen Opens Del. Ch. 11 With $226M In Debt
- Discovery Fraud Kills Suppliers' Privilege In Test Strips Row
- You're Perfect, Now Change: Perfectionism Hurts Lawyers
- Medical Device Co. Says Atty's Consultant Scam Cost It $1.8M
- Cook Medical's Vein Filter Suit Tossed As Time-Barred
- 11th Circ. Creates Headaches For Judges, Defense Attorneys
- Clorox Swallows Vitamin Maker In $700M Deal
- Grassley, Feinstein Debate Judicial Vetting, Obstruction
- Why The 'Blue Slip' Battles Are Becoming White Hot
- Senior Judges Fill The Void Left By Rampant Vacancies
- Walgreens Must Face Bulk Of Suit Over Rx Club Prices
- How Far Right Can The President Pull The Courts?
- Impax Heads To Rare Trial In Pay-For-Delay Case
- Tribe Says PTAB Can't Weigh Restasis Patents During Appeal
- Dr. Reddy's Escapes FCA Suit Over Drug Packaging
- FDA Accuses Scope Makers Of Flouting Safety Studies
- Health Hires: Aronberg, Bracewell, Miles, Polsinelli, Sidley
- Abbott Unit Covered By Patent Safe Harbor, Magistrate Says
- Firm's Suit Over Fees In Novartis Row Paused Over Atty Exit
- Texas Pharma Delivery Co. Wins $24M In Tech Battle
- GlaxoSmithKline 'Pay For Delay' Suit Heads To EU Court
- Johnson & Johnson Hit With $35M Verdict In Pelvic Mesh Trial
- Ex-Biotech CEO Blasts SEC's 'Guilt By Association' Suit
- FTC Materials Barred In Imminent Solodyn Pay-For-Delay Trial
- The New USPTO Examiner Manual And 102(e) Prior Art
- Shkreli Gets 7 Years In Prison For Securities Fraud
- 3rd Circ. Gets It Partly Right On Component Preemption
- Genentech Fights For $5.8M In 'Exceptional' IP Attys Fees
- Soon-Shiong Firm Fights $47M Post-Merger Cash Tap Suit
- 11th Circ. Upholds Yale Doc's Fee Award In Defamation Suit
- Cancer-Focused Biotech Co. Prices $60M IPO At Low End
- 7th Circ. Won't Revive Knee Implant MDL Bellwether
- Baker McKenzie Snags 5 Ex-Hogan Attys, Opens LA Office
- DOJ Leaning More On FCA In Fight Against Opioid Abuse
- Calif. Claims Cancer Nonprofit Inflated Value By Millions
- PTAB Hands Out Mixed Results In Sleep-Aid Challenges
- Fed. Circ. Says Exergen Thermometer Patents Survive Mayo
- USPTO Defends Charging Attys' Fees At Full Fed. Circ.
- Parkinson's-Fighting Biotech Snags $75M In Series A Funding
- Heart Pump Maker Pays $3.1M To Settle Kickback Charges
- Littler Adds Ex-Alexion Pharma Counsel As Shareholder
- Pot Business Asks 10th Circ. For Equal Treatment From IRS
- 5 Sens. Introduce Bill To Bar Tribal Immunity Deals At PTAB
- Don't Revive Restasis Patents, Generic Cos. Urge Fed. Circ.
- BioCryst Shareholders Sue Over Idera Merger Plan
- Bone Broth Nutrition Biz Reaps $103M In Funding
- Goldberg Segalla Boosts NY IP Group With Ex-Polsinelli Atty
- Will High Court Provide Clarity On 'Clear Evidence'?
- Roche Released From Suit Over Man's Bowel Disease
- Pay Our Attorneys' Fees, USPTO Says, Even When We Lose
- Pharma Co. Tells CIT Its Drugs Are Made In U.S., Not India
- Shkreli Attys Call 15-Year Sentence 'Severe,' Ask For 1.5
- McKesson Says It Acted On Compliance Concerns In 2008
- Retrial Begins In Original Testosterone MDL Bellwether
- EPO Again Reports Record High In Patents Granted
- Opioid MDL To Get Litigation Track Amid Settlement Talks
- Blue Cross, Takeda Settle Actos Cancer Claims
- Calif. Court Restores Patient's $4.5M Win In Hip Defect Suit
- Insurer Needn't Cover $5M HIPAA Probe Costs, 9th Circ. Says
- Bayer, J&J Look To Bar Amended Master Xarelto Complaint
- What Happens If The DOJ Joins The Opioid MDL?
- Valeant Looks To Shake Investment Fund's State RICO Claims
- Amgen Says FDA Flouted Own Rules In Calcium Drug Row
- Cosmetics Companies Using Instagram Face Regulatory Risk
- Deputy AG Asks For Insurers' Help To End Opioid Crisis
- DOJ Civil Division Pick Promises A False Claims Focus
- Dietary Supplements And FDA: Potential For Partnership?
- Cannabis' CEQA Challenge
- Legal Group Urges 1st Circ. To Flip Asacol Class Cert.
- 3rd Circ. Gives 'Hybrid' Med Devices New Liability Shield
- Wilson Sonsini Snags DOJ, FTC Vet From Gibson Dunn
- FDA Backs 23andMe Tests For Breast Cancer Risks
- Teva Blocking Senate Opioid Investigation, McCaskill Says
- Gov't Urges Justices To Flip Vitamin C Price-Fixing Decision
- Feds Seek 15-Year Term For Martin Shkreli
- FDA Warning Wire: Bevy Of Big-Name Cos. Targeted
- Barnes & Thornburg Opens Office With Ex-Cooley Partner
- Express Scripts Escapes Processing-Fee Suit
- Tribes Hit Pharma Cos. With Suit Over Opioid Crisis
- Where White Collar Enforcement Is Heading
- Searching For 'Act Of Infringement' Under Hatch-Waxman
- 10 Tips For Working With IT To Preserve Data
- Chinese Vaccine Co. Sues 'Dissident' Shareholders Over Coup
- Riker Danzig, Cole Schotz Launch NJ Cannabis Practices
- J&J Unit Can't Shake $15M Pelvic Mesh Verdict In NJ
- Whistleblowers Assail Gilead's Escobar Defense At High Court
- 2 Firms Edge Ahead In February Aided By Blank Check IPOs
- Fujifilm Sues Hologic For Mammography Patent Infringement
- PTAB Upholds Claims Of 2 Glucose Monitoring Patents
- DEA Agrees To Large Data Release In Opioid MDL
- Kilpatrick Townsend Hires Ex-Holland & Knight IP Partner
- Tech 'Unicorn' Leads 3 Cos. To Launch IPOs Totaling $286M
- Bill Would Boost Tribes' Access To Opioid Treatment Funds
- Justices Spurn Endo, NH Row Over Counsel In Opioid Probe
- Shkreli Must Give Up $7.3M, Wu-Tang Clan Album
- How To Guide Your Client's New Drug Past An FDA Quick Kill
- Profs Tell High Court 2nd Circ. Wrong On Chinese Exporters
- J&J Asks 3rd Circ. To End Suit Over Talc-Based Baby Powder
- Exploring Limits Of Anti-Kickback Law Employee Safe Harbor
- Class Action Lawyers Behaving Badly
- Mylan Can't Escape Celgene's Suit Over Skin Cancer Patent
- Juno Investor Seeks Records To Look Into $9B Celgene Deal
- NJ Firefighter Cops To Role In $50M Drug Fraud Scheme
- Cherokee Nation, Drug Cos. Wrangle Over Opioid Suits
- FCA Decision Tracker: Continued Interpretations Of Escobar
- Health Care Cos. Lose Class Bid In Janssen Junk Fax Suit
- Fed. Court Won't Hear Shumaker Loop IP Malpractice Suit
- Insurers Defend $67M Antitrust Win Amid Mylan Appeal
- FasciaBlaster Inventor Sanctioned In Failed Defamation Suit
- Lawyers Needed To Cut Through The Weeds Of Pot M&A
- Brand Battles: 'Lord Of The Rings,' Bayer, MLB, Scotch Whisky
- Deals Rumor Mill: SlimFast, United Grinding, IGM Resins
- Par Pharma Blocks Blood Pressure Drug Rival
- Tricida Secures $100M In Debt Financing For Latest Drug
- Impermissibly Redefining 'Long-Felt Need' Using Hindsight
- Jurisdiction Issues Dog Multistate Class Actions
- 'Revolving Door' At DEA Faces Scrutiny In Opioid MDL
- 3rd Circ. Nixes Part Of 'Hybrid' Medical Device Suit
- Trump May 'Do Some Litigation' Against Opioid Cos.
- Wrist Wear Co. Hits Ch. 11 With Plans To Sell IP, Sue Apple
- Valeant To Shell Out $58M To End Solodyn Pay-For-Delay MDL
- Ex-Hunton Atty Urges 2nd Circ. To Undo Insider Trading Rap
- Jury Says Omnicare Didn't Misclassify Drivers In FLSA Suit
- Details Emerge On DEA Data Release In Opioid MDL
- Allergan, Tribe Rush To Appeal PTAB Decision To Review IP
- Justices Urged To Reverse 'Indefensible' On-Sale Bar Ruling
- Belgian, French Cartel Watchdogs Raid Cosmetics Companies
- PTAB Upholds Eye Treatment Tool Patent
- Make An Informed Choice About Arbitration
- FTC, NY Assail Toss Of Memory Booster Suit At 2nd Circ.
- Miami-Dade County Hires Legal Team To Launch Opioid Suit
- Barnes & Thornburg Adds IP, Corporate Attys In Chicago
- Mintz Levin Adds Morgan Lewis Tech Duo In Boston
- Protecting Privilege In Litigation Financing Negotiations